Skip to main content
Top
Published in: EJNMMI Research 1/2020

01-12-2020 | Tuberculosis | Original research

Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response

Authors: Stephanus T. Malherbe, Ray Y. Chen, Patrick Dupont, Ilse Kant, Magdalena Kriel, André G. Loxton, Bronwyn Smith, Caroline G. G. Beltran, Susan van Zyl, Shirely McAnda, Charmaine Abrahams, Elizna Maasdorp, Alex Doruyter, Laura E. Via, Clifton E. Barry III, David Alland, Stephanie Griffith- Richards, Annare Ellman, Thomas Peppard, John Belisle, Gerard Tromp, Katharina Ronacher, James M. Warwick, Jill Winter, Gerhard Walzl

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Background

There is a growing interest in the use of F-18 FDG PET-CT to monitor tuberculosis (TB) treatment response. Tuberculosis lung lesions are often complex and diffuse, with dynamic changes during treatment and persisting metabolic activity after apparent clinical cure. This poses a challenge in quantifying scan-based markers of burden of disease and disease activity. We used semi-automated, whole lung quantification of lung lesions to analyse serial FDG PET-CT scans from the Catalysis TB Treatment Response Cohort to identify characteristics that best correlated with clinical and microbiological outcomes.

Results

Quantified scan metrics were already associated with clinical outcomes at diagnosis and 1 month after treatment, with further improved accuracy to differentiate clinical outcomes after standard treatment duration (month 6). A high cavity volume showed the strongest association with a risk of treatment failure (AUC 0.81 to predict failure at diagnosis), while a suboptimal reduction of the total glycolytic activity in lung lesions during treatment had the strongest association with recurrent disease (AUC 0.8 to predict pooled unfavourable outcomes). During the first year after TB treatment lesion burden reduced; but for many patients, there were continued dynamic changes of individual lesions.

Conclusions

Quantification of FDG PET-CT images better characterised TB treatment outcomes than qualitative scan patterns and robustly measured the burden of disease. In future, validated metrics may be used to stratify patients and help evaluate the effectiveness of TB treatment modalities.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO. Global tuberculosis report 2018. 2018. WHO. Global tuberculosis report 2018. 2018.
2.
go back to reference de SE NS, Mancuzo EV, Sulmonetti N, Sacchi FPC, de Souza Viana V, Netto EM, Miranda SS, Croda J. Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. Braz J Infect Dis. 2015;19(5):492–7.CrossRef de SE NS, Mancuzo EV, Sulmonetti N, Sacchi FPC, de Souza Viana V, Netto EM, Miranda SS, Croda J. Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients. Braz J Infect Dis. 2015;19(5):492–7.CrossRef
3.
go back to reference Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. George Respiratory Questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest. 2007;132(5):1591–8.PubMedCrossRef Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. George Respiratory Questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest. 2007;132(5):1591–8.PubMedCrossRef
4.
go back to reference Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, Sodemann M. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111–20.PubMedCrossRef Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, Sodemann M. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111–20.PubMedCrossRef
5.
go back to reference Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007;131(6):1817–24.PubMedCrossRef Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007;131(6):1817–24.PubMedCrossRef
6.
go back to reference Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55(1):32–8.PubMedPubMedCentralCrossRef Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55(1):32–8.PubMedPubMedCentralCrossRef
7.
go back to reference Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. J Coll Physicians Surg Pak. 2010;20(8):542–4.PubMed Baig IM, Saeed W, Khalil KF. Post-tuberculous chronic obstructive pulmonary disease. J Coll Physicians Surg Pak. 2010;20(8):542–4.PubMed
8.
go back to reference Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010;10:259.PubMedPubMedCentralCrossRef Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010;10:259.PubMedPubMedCentralCrossRef
9.
go back to reference Chang S, Cataldo JK. A systematic review of global cultural variations in knowledge, attitudes and health responses. Int J Tuberc Lung Dis. 2014;18:168–73.PubMedCrossRef Chang S, Cataldo JK. A systematic review of global cultural variations in knowledge, attitudes and health responses. Int J Tuberc Lung Dis. 2014;18:168–73.PubMedCrossRef
11.
go back to reference Johnson JL, Hadad DJ, Dietze R, Maciel ELN, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63.PubMedPubMedCentralCrossRef Johnson JL, Hadad DJ, Dietze R, Maciel ELN, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–63.PubMedPubMedCentralCrossRef
12.
go back to reference Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N’Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98.PubMedCrossRef Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N’Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–98.PubMedCrossRef
13.
go back to reference Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson ALE, McHugh TD, Butcher PD, Mitchison DA. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608.PubMedPubMedCentralCrossRef Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson ALE, McHugh TD, Butcher PD, Mitchison DA. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–608.PubMedPubMedCentralCrossRef
14.
go back to reference Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87.PubMedPubMedCentralCrossRef Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–87.PubMedPubMedCentralCrossRef
15.
go back to reference Warner DF, Mizrahi V. Shortening treatment for tuberculosis - back to basics. N Engl J Med. 2014;371(17):1642–3.PubMedCrossRef Warner DF, Mizrahi V. Shortening treatment for tuberculosis - back to basics. N Engl J Med. 2014;371(17):1642–3.PubMedCrossRef
16.
go back to reference Marx FM, Dunbar R, Enarson DA, Williams BG, Warren RM, Van Der Spuy GD, Van Helden PD, Beyers N. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis. 2014;58(12):1676–83.PubMedCrossRef Marx FM, Dunbar R, Enarson DA, Williams BG, Warren RM, Van Der Spuy GD, Van Helden PD, Beyers N. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis. 2014;58(12):1676–83.PubMedCrossRef
17.
go back to reference Seon HJ, Kim YI, Lim SC, Kim YH, Kwon YS. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014;18:341–6.PubMedCrossRef Seon HJ, Kim YI, Lim SC, Kim YH, Kwon YS. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014;18:341–6.PubMedCrossRef
18.
go back to reference Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja KE, Pontororing GJ, Anstey NM, Kelly PM. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010;65(10):863–9.PubMedCrossRef Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja KE, Pontororing GJ, Anstey NM, Kelly PM. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010;65(10):863–9.PubMedCrossRef
19.
go back to reference Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PPJ, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, Mchugh TD, Gillespie SH, Diacon AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2014;2600(13):1–9. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PPJ, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, Mchugh TD, Gillespie SH, Diacon AH, Hoelscher M. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med. 2014;2600(13):1–9.
20.
go back to reference Lahtinen SJ, Ahokoski H, Reinikainen JP, Gueimonde M, Nurmi J, Ouwehand AC, Salminen SJ. Degradation of 16S rRNA and attributes of viability of viable but nonculturable probiotic bacteria. Lett Appl Microbiol. 2008;46:693–8.PubMedCrossRef Lahtinen SJ, Ahokoski H, Reinikainen JP, Gueimonde M, Nurmi J, Ouwehand AC, Salminen SJ. Degradation of 16S rRNA and attributes of viability of viable but nonculturable probiotic bacteria. Lett Appl Microbiol. 2008;46:693–8.PubMedCrossRef
21.
go back to reference Malherbe ST, Kleynhans L, Walzl G. The potential of imaging tools as correlates of infection and disease for new TB vaccine development. Semin Immunol. 2018;39:73–90.PubMedCrossRef Malherbe ST, Kleynhans L, Walzl G. The potential of imaging tools as correlates of infection and disease for new TB vaccine development. Semin Immunol. 2018;39:73–90.PubMedCrossRef
22.
go back to reference Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S. Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol. 2014;41(10):777–84.PubMedPubMedCentralCrossRef Johnson DH, Via LE, Kim P, Laddy D, Lau CY, Weinstein EA, Jain S. Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol. 2014;41(10):777–84.PubMedPubMedCentralCrossRef
23.
go back to reference Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20(3):287–93.PubMedCrossRef Vorster M, Sathekge MM, Bomanji J. Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20(3):287–93.PubMedCrossRef
24.
go back to reference Kriel M, Lotz JW, Kidd M, Walzl G. Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015;19(11):1354–60.PubMedCrossRef Kriel M, Lotz JW, Kidd M, Walzl G. Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2015;19(11):1354–60.PubMedCrossRef
25.
go back to reference Yeon JJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. Am J Roentgenol. 2008;191(3):834–44.CrossRef Yeon JJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. Am J Roentgenol. 2008;191(3):834–44.CrossRef
26.
go back to reference Bomanji JB, Gupta N, Gulati P, Das CJ. Imaging in tuberculosis. Cold Spring Harb Perspecti Med. 2015;5(a017814):1–23. Bomanji JB, Gupta N, Gulati P, Das CJ. Imaging in tuberculosis. Cold Spring Harb Perspecti Med. 2015;5(a017814):1–23.
27.
go back to reference Stelzmueller I, Huber H, Wunn R, Hodolic M, Mandl M, Schinko H, Lamprecht B, Fellner F, Skanjeti A, Giammarile F, Colletti PM, Gabriel M, Rubello D. 18F-FDG PET/CT in the initial assessment and for follow-up in patients with tuberculosis. Clin Nucl Med. 2015;41(4):187–94.CrossRef Stelzmueller I, Huber H, Wunn R, Hodolic M, Mandl M, Schinko H, Lamprecht B, Fellner F, Skanjeti A, Giammarile F, Colletti PM, Gabriel M, Rubello D. 18F-FDG PET/CT in the initial assessment and for follow-up in patients with tuberculosis. Clin Nucl Med. 2015;41(4):187–94.CrossRef
28.
go back to reference Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. 2009;36(4):632–9.PubMedCrossRef Demura Y, Tsuchida T, Uesaka D, Umeda Y, Morikawa M, Ameshima S, Ishizaki T, Fujibayashi Y, Okazawa H. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. 2009;36(4):632–9.PubMedCrossRef
29.
go back to reference Lin PL, Ford CB, Coleman MT, Myers AJ, Ioerger T, Sacchettini J, Fortune SM, Joanne L. Sterilization of granulomas is common in both active and latent tuberculosis despite extensive within-host variability in bacterial killing. Nat Med. 2014;20(1):75–9.PubMedCrossRef Lin PL, Ford CB, Coleman MT, Myers AJ, Ioerger T, Sacchettini J, Fortune SM, Joanne L. Sterilization of granulomas is common in both active and latent tuberculosis despite extensive within-host variability in bacterial killing. Nat Med. 2014;20(1):75–9.PubMedCrossRef
30.
go back to reference Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother. 2009;53(11):4879–84.PubMedPubMedCentralCrossRef Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother. 2009;53(11):4879–84.PubMedPubMedCentralCrossRef
31.
go back to reference Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon Y-S, Dreher MR, Kastenmayer RJ, Laymon CM, Carny JE, Flynn JL, Herscovitch P, Barry CE. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother. 2012;56(8):4391–402.PubMedPubMedCentralCrossRef Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon Y-S, Dreher MR, Kastenmayer RJ, Laymon CM, Carny JE, Flynn JL, Herscovitch P, Barry CE. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [18F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother. 2012;56(8):4391–402.PubMedPubMedCentralCrossRef
32.
go back to reference Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. Early events in mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2006;74(7):3790–803.PubMedPubMedCentralCrossRef Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. Early events in mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2006;74(7):3790–803.PubMedPubMedCentralCrossRef
33.
go back to reference Lin PL, Coleman T, Carney JPJ, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE, Flynn JL. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother. 2013;57(9):4237–44.PubMedPubMedCentralCrossRef Lin PL, Coleman T, Carney JPJ, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE, Flynn JL. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother. 2013;57(9):4237–44.PubMedPubMedCentralCrossRef
34.
go back to reference Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL. Early changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2014;82(6):2400–4.PubMedPubMedCentralCrossRef Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL. Early changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun. 2014;82(6):2400–4.PubMedPubMedCentralCrossRef
35.
go back to reference Allison M, Murawski SG, Harper JS, Klunk M, Younes L, Jain SK, Jedynak BM. Imaging the evolution of reactivation pulmonary tuberculosis in mice using 18 F-FDG PET. J Nucl Med. 2014;55(10):1726–9.CrossRef Allison M, Murawski SG, Harper JS, Klunk M, Younes L, Jain SK, Jedynak BM. Imaging the evolution of reactivation pulmonary tuberculosis in mice using 18 F-FDG PET. J Nucl Med. 2014;55(10):1726–9.CrossRef
36.
go back to reference Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, Doucet-Populaire F, Boué F. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis. 2012;16(9):1180–5.PubMedCrossRef Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, Doucet-Populaire F, Boué F. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis. 2012;16(9):1180–5.PubMedCrossRef
37.
go back to reference Dureja S, Sen I, Acharya S. Potential role of F18 FDG PET-CT as an imaging biomarker for the noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational. Eur Spine J. 2014;23(11):2449–54.PubMedCrossRef Dureja S, Sen I, Acharya S. Potential role of F18 FDG PET-CT as an imaging biomarker for the noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational. Eur Spine J. 2014;23(11):2449–54.PubMedCrossRef
38.
go back to reference Sathekge M, Maes A, Van De Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43(5):349–66.PubMedCrossRef Sathekge M, Maes A, Van De Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43(5):349–66.PubMedCrossRef
39.
go back to reference Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med. 2011;52(6):880–5.PubMedCrossRef Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med. 2011;52(6):880–5.PubMedCrossRef
40.
go back to reference Stelzmueller I, Huber H, Wunn R, Hodolic M, Mandl M, Lamprecht B, Schinko H, Fellner F, Skanjeti A, Giammarile F, Colletti PM, Rubello D, Gabriel M. 18F-FDG PET / CT in the initial assessment and for follow-up in patients with tuberculosis. Clin Nucl Med. 2016;41(4):187–94.CrossRef Stelzmueller I, Huber H, Wunn R, Hodolic M, Mandl M, Lamprecht B, Schinko H, Fellner F, Skanjeti A, Giammarile F, Colletti PM, Rubello D, Gabriel M. 18F-FDG PET / CT in the initial assessment and for follow-up in patients with tuberculosis. Clin Nucl Med. 2016;41(4):187–94.CrossRef
41.
go back to reference Choi J, Jhun B, Hyun S, Chung M, Koh W-J. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography for assessing treatment response of pulmonary multidrug-resistant tuberculosis. J Clin Med. 2018;7(12):559.PubMedCentralCrossRef Choi J, Jhun B, Hyun S, Chung M, Koh W-J. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography for assessing treatment response of pulmonary multidrug-resistant tuberculosis. J Clin Med. 2018;7(12):559.PubMedCentralCrossRef
42.
go back to reference Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park S-K, Cho S-N, Barry CE. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014;6(265):265ra166.PubMedPubMedCentralCrossRef Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park S-K, Cho S-N, Barry CE. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014;6(265):265ra166.PubMedPubMedCentralCrossRef
43.
go back to reference Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park S-K, Cho S-N, Barry CE. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. 2014;6(265):265ra167.PubMedPubMedCentralCrossRef Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park S-K, Cho S-N, Barry CE. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. 2014;6(265):265ra167.PubMedPubMedCentralCrossRef
44.
go back to reference Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, Winter J, Walzl G, Lucas L, der Spuy GV, Stanley K, Theart L, Smith B, Burger N, Beltran CGG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Kogelenberg C, Vorster M, Griffith-Richards S. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016;22:1094–100.PubMedPubMedCentralCrossRef Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, Winter J, Walzl G, Lucas L, der Spuy GV, Stanley K, Theart L, Smith B, Burger N, Beltran CGG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Kogelenberg C, Vorster M, Griffith-Richards S. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016;22:1094–100.PubMedPubMedCentralCrossRef
45.
go back to reference Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, Dodd LE, Via LE, Barry CE, Walzl G, Alland D. Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One. 2016;11(8):e0160062.PubMedPubMedCentralCrossRef Shenai S, Ronacher K, Malherbe S, Stanley K, Kriel M, Winter J, Peppard T, Barry CE, Wang J, Dodd LE, Via LE, Barry CE, Walzl G, Alland D. Bacterial loads measured by the Xpert MTB/RIF assay as markers of culture conversion and bacteriological cure in pulmonary TB. PLoS One. 2016;11(8):e0160062.PubMedPubMedCentralCrossRef
46.
go back to reference Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE, Du Plessis N, Loxton AG, Chegou NN, Lee M. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis. 2017;107:48–58.PubMedCrossRef Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE, Du Plessis N, Loxton AG, Chegou NN, Lee M. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis. 2017;107:48–58.PubMedCrossRef
47.
go back to reference Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Iii CEB, Griffith-richards S, Ellman A, Ronacher K, Winter J, Walzl G. A semi-automatic technique to quantify complex tuberculous lung lesions on F-fluorodeoxyglucose positron emission tomography / computerised tomography images. EJNMMI Res. 2018;8(55):1–14. Malherbe ST, Dupont P, Kant I, Ahlers P, Kriel M, Loxton AG, Chen RY, Via LE, Thienemann F, Wilkinson RJ, Iii CEB, Griffith-richards S, Ellman A, Ronacher K, Winter J, Walzl G. A semi-automatic technique to quantify complex tuberculous lung lesions on F-fluorodeoxyglucose positron emission tomography / computerised tomography images. EJNMMI Res. 2018;8(55):1–14.
50.
go back to reference Fitzgerald BL, Islam MN, Graham B, Mahapatra S, Webb K, Boom WH, Malherbe ST, Joloba ML, Johnson JL, Winter J, Walzl G, Belisle JT. Elucidation of a novel human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy. ACS Infect Dis. 2018;5(3):353–64.PubMedCentralCrossRef Fitzgerald BL, Islam MN, Graham B, Mahapatra S, Webb K, Boom WH, Malherbe ST, Joloba ML, Johnson JL, Winter J, Walzl G, Belisle JT. Elucidation of a novel human urine metabolite as a seryl-leucine glycopeptide and as a biomarker of effective anti-tuberculosis therapy. ACS Infect Dis. 2018;5(3):353–64.PubMedCentralCrossRef
51.
go back to reference Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry CE III. Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Res. 2017;1:9.PubMedPubMedCentralCrossRef Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry CE III. Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Res. 2017;1:9.PubMedPubMedCentralCrossRef
52.
go back to reference Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL. Early changes by 18F-PET-CT predict outcome after M. tuberculosis infection in cynomolgus macaques. Infect Immun. 2014;82(6):2400–4.PubMedPubMedCentralCrossRef Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, Klein E, Lin PL. Early changes by 18F-PET-CT predict outcome after M. tuberculosis infection in cynomolgus macaques. Infect Immun. 2014;82(6):2400–4.PubMedPubMedCentralCrossRef
53.
go back to reference Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–93.PubMedCrossRef Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358(9294):1687–93.PubMedCrossRef
54.
go back to reference Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731–6.PubMedCrossRef Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38(5):731–6.PubMedCrossRef
Metadata
Title
Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response
Authors
Stephanus T. Malherbe
Ray Y. Chen
Patrick Dupont
Ilse Kant
Magdalena Kriel
André G. Loxton
Bronwyn Smith
Caroline G. G. Beltran
Susan van Zyl
Shirely McAnda
Charmaine Abrahams
Elizna Maasdorp
Alex Doruyter
Laura E. Via
Clifton E. Barry III
David Alland
Stephanie Griffith- Richards
Annare Ellman
Thomas Peppard
John Belisle
Gerard Tromp
Katharina Ronacher
James M. Warwick
Jill Winter
Gerhard Walzl
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-0591-9

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue